Board of Directors
Jens Due Olsen has over 30 years of experience in leadership positions in Danish and international industrial, financial and technology companies, including medico technology. Jens currently serves as the Chair of the Board of Directors at NKT Holding and the privately owned European Energy A/S. Jens also holds the position of Vice Chair of the Board of Directors at KMD A/S, a subsidiary of NEC Corp. Inc., and has advisory roles with several private equity and venture capital firms, including JOLT S.A. Additionally, Jens is Chair of the not-for-profit organization Børnebasketfonden. Jens Due Olsen has previously held leadership and executive positions at A.P. Moller-Maersk, FLSmidth and GN Store Nord, amongst others.
Jens Due Olsen is considered independent according to the Danish Corporate Governance Recommendations.
A member of BioPorto’s Board of Directors since 2024, Henrik Juuel has been the Executive Vice President and Chief Financial Officer at Bavarian Nordic since 2018. Prior to joining Bavarian Nordic, Henrik served as CFO at Orexo AB and held senior positions at several large and diverse organizations, including Group CFO of Virgin Mobile (Central and Eastern Europe), CFO of GN ReSound, and CFO of NNE Pharmaplan. He began his career at Novo Nordisk in 1992, where he held several senior finance positions in Denmark and abroad during his 15-year tenure with the company. Henrik holds an M.Sc. in Economics and Finance.
Henrik Juuel is considered independent according to the Danish Corporate Governance Recommendations.
A member of BioPorto’s Board of Directors since 2024, Mats Thorén has 25 years of financial market experience, specializing in healthcare through roles in equity analysis and corporate finance. He has spent 19 years as a Healthcare investment expert, working with firms like Nalka Life Science AB and MedCap AB, and now leads Vixco Capital as CEO and board member. Mats holds board positions at FluoGuide A/S, Xbrane BioPharma AB, Arcoma AB, C-Rad AB and Herantis Pharma Oy, and has previously held board roles at Cellartis AB, and others. His educational background includes Economics, focusing on Accounting and Financial Economics, and medical studies at the Karolinska Institute in Stockholm.
Mats Thorén is considered independent according to the Danish Corporate Governance Recommendations.
Donna Haire has over 30 years of leadership experience in healthcare, pharmaceuticals, and medical devices. She is a board member and CEO of The Eriah Group, Inc., a global consulting firm specializing in turn-key R&D operations, including regulatory, quality, clinical, and medical affairs for drugs, biologics, medical devices, in vitro diagnostics, and combination products. She has held executive roles at On Target Laboratories, Bayer, and AngioDynamics, and senior positions at Philips Healthcare, Medtronic, and STERIS. She currently serves on the boards of FluoGuide A/S and Sedana Medical AB. Donna holds an M.S. in Biology from Cleveland State University and a B.S. in Biology from The University of Akron.
In 2023 & 2024, Donna Haire provided consultancy services for the Company in connection with the pediatric US FDA clearance, and is thus not considered independent according to the Danish Corporate Governance Recommendations.
Board Committees
BioPorto’s Board Committees are preparatory bodies to assist the Board of Directors in its work and shall provide oversight and monitoring functions over the business.